Molecular diagnostics in clinical oncology: an overview

Молекулярная диагностика в клинической онкологии: обзор
Анна Петровна Соколенко, Евгений Наумович Имянитов
2025-07-17

circulating tumor DNA (ctDNA)germline pathogenic variantsliquid biopsymolecular diagnosticspredictive tests for drug-target matching
Molecular diagnostics has become an integral part of modern clinical oncology. There are several dozen hereditary cancer syndromes; the detection of germline pathogenic variants in tumor-predisposing genes allows for the identification of subjects at-risk as well as guides the administration of cytotoxic and targeted drugs. The development of predictive tests for personalized drug-target matching is the best-known achievement of molecular oncology. For the time being, these assays are routinely utilized for the management of lung, breast, ovarian, colorectal, thyroid, biliary tract, endometrial, urothelial, and other malignancies. We are currently witnessing the emergence of practical applications of liquid biopsy. The detection of circulating tumor DNA (ctDNA) is a highly sensitive and specific procedure, which is currently used for the detection of secondary drug-resistant mutations, and holds great promise for the monitoring of malignant disease in oncological patients and early cancer detection in healthy individuals. While the utilization of molecular tests is currently limited to particular categories of cancer patients, their use is likely to become significantly more widespread in the near future. This trend will affect educational standards, requiring practicing physicians to become more familiar with molecular biology, and, vice versa, claiming some fluency in clinical oncology from laboratory specialists.
1
Current use of molecular tests is limited to particular cancer patient categories, but their clinical application is expected to become significantly more widespread.
2
Detection of germline pathogenic variants in tumor-predisposing genes enables identification of at-risk individuals and guides cytotoxic and targeted drug administration.
3
Liquid biopsy and detection of circulating tumor DNA (ctDNA) are highly sensitive and specific for detecting secondary drug-resistant mutations and show promise for disease monitoring and early cancer detection.
4
Predictive molecular tests for personalized drug-target matching are established and routinely used in management of lung, breast, ovarian, colorectal, thyroid, biliary tract, endometrial, urothelial, and other malignancies.
5
Wider adoption of molecular diagnostics will require updated education: clinicians need greater molecular biology knowledge and laboratory specialists need increased clinical oncology fluency.

Molecular diagnostic assays (including germline testing and circulating tumor DNA/liquid biopsy) used in clinical oncology

Their applications and clinical utility for identifying hereditary cancer predisposition, guiding targeted and cytotoxic therapy selection, detecting secondary drug-resistant mutations, monitoring malignant disease, and early cancer detection

Publication Details
Publication Date
2025-07-17
Journal
Publisher
ISSN
Cited by
2
Access Type
Author Information
Authors
Анна Петровна Соколенко
Евгений Наумович Имянитов
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%